These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36274215)

  • 1. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
    Zhang S; Yang L; Yang Y; Xin Y; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
    Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
    J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy.
    Wang Y; Wang W; Zhang T; Yang Y; Wang J; Li C; Xu X; Wu Y; Jiang Y; Duan J; Wang L; Bi N
    J Natl Cancer Cent; 2024 Jun; 4(2):177-187. PubMed ID: 39282582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
    Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
    BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
    Bar J; Esteban E; Rodríguez-Abreu D; Aix SP; Szalai Z; Felip E; Gottfried M; Provencio M; Robinson A; Fülöp A; Rao SB; Camidge DR; Speranza G; Townson SM; Kobie J; Ayers M; Dettman EJ; Hunkapiller N; McDaniel R; Jung B; Burkhardt D; Mauntz R; Csőszi T
    Lung Cancer; 2024 Apr; 190():107506. PubMed ID: 38422883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
    Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML; Dakhil CSR; Stella P; Jin Y; Shames DS; Schleifman E; Fabrizio DA; Phan S; Socinski MA
    Nat Med; 2022 May; 28(5):939-945. PubMed ID: 35422531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial.
    Park CK; Jun HR; Oh HJ; Lee JY; Cho HJ; Kim YC; Lee JE; Yoon SH; Choi CM; Lee JC; Lee SY; Lee SY; Chun SM; Oh IJ
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 15. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
    Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
    Ma Y; Li Q; Du Y; Cai J; Chen W; Zhao G; Liu X; Li H; Ma L; Huang Y; Zhou Y
    Front Oncol; 2021; 11():640761. PubMed ID: 34055609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
    Jiang T; Chen J; Xu X; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Zhang Y; Zhang J; Yang Z; Shi W; Zou J; Zhou C; Ren S
    Mol Cancer; 2022 Jan; 21(1):4. PubMed ID: 34980131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.